Orig3n

Orig3n is a biotechnology company headquartered in Boston, Massachusetts developing personalized regenerative medicine treatments based on patient genetic profiles that was founded on April 10, 2014 by Kate Blanchard and Robin Smith.

Orig3n specialized in developing personalized regenerative medicine treatments for rare and genetically inherited diseases. They offer medical practitioners and scientific researchers a bio-repository of induced pluripotent stem cells for developing new medical treatments called LifeCapsule, and a platform for creating cellular models using the LifeCapsule bio-repository called LifeSystems.

On February 15, 2015 Orig3n completed a venture capital funding round with $3.1 million in funding from Mountain Group Capital, KTB Ventures, Hatteras Venture Partners, and 180 Degrees Capital.

On December 12, 2015 Orig3n completed their series A funding round with $12.5 million in funding from Syno Capital (lead investor), Hatteras Venture Partners, (lead investor), Mountain Group Capital, LabCorp, KTB-Korus Fund, Defta Partners, and 180 Degree Capital.

On June 27, 2017 Orig3n completed another venture capital round with $20 million in funding from Hatteras Venture Partners (lead investor), Syno Capital, Spectrum Health Ventures, MGC Venture Partners, LabCorp, KTB-Korus Fund, Defta Partners, and 180 Degree Capital.

On June 12, 2018 Orig3n completed their series B funding round with an undisclosed amount of funding (of at least $14.4 million) from Haitong International Securities Group (lead investor), Vectr Ventures, Spectrum Health Ventures, Mountain Group Capital, MMIC Investment Holdings, LabCorp, KTB Ventures, Hatteras Venture Partners, Defta Partners, Alexandria Venture Investments, and 180 Degree Capital.

On January 15, 2019 Orig3n became the Official Genetics Partner of the U.S. Ski & Snowboard Team. Orig3n will be helping members of the Ski & Snowboard team in Park City, Utah develop specialized health programs for improving their training, performance, and recovery.